Karyopharm Therapeutics Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Karyopharm Therapeutics Inc. (KPTI) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $67.85 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-24.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2021-02-24
- Karyopharm Therapeutics Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2018 was $67.85M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|
| 2018-12-31 | $67.85M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |